First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors
Research payments
$13,818,252
Through program year 2024, $13,818,252 in research payments was reported against First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors, across 36 payments, paid by Merck Sharp & Dohme Corporation.
- Paid by
- Merck Sharp & Dohme Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $7,210,968 | 15 |
| 2023 | Research | $5,367,804 | 13 |
| 2022 | Research | $1,239,480 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- John Kaczmar Charleston, SC Named on 3 payments
- Christine Chung Tampa, FL Named on 3 payments
- Van Morris Durham, NC Named on 2 payments
- Glenn Hann Dansville, NY Named on 2 payments
- Emrullah Yilmaz Albuquerque, NM Named on 2 payments
- Deborah Wong Los Angeles, CA Named on 2 payments
- Michael Gibson Nashville, TN Named on 2 payments
- Paul Paik New York, NY Named on 2 payments
- Dan Zandberg Baltimore, MD Named on 1 payment
- Catherine Shu New York, NY Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.